333 Sylvan Ave., Suite 101
Englewood Cliffs, NJ 07632

Tel:   212-740-6920
Email:

About Forticell Bioscience, Inc.

 

About the Company

Mission Statement

Management Team

Board of Directors

Location & Directions

Careers

Whats New

Archives

Press News (Archives)

1-31-08
FORTICELL BIOSCIENCE CHIEF EXECUTIVE OFFICER INTERVIEWED ON CEOCAST.COM
Read More

 

1-22-08
WALLST.NET ANNOUNCES UPCOMING INTERVIEW WITH PRESIDENT OF FORTICELL BIOSCIENCE
Read More

 

1-14-08
FORTICELL BIOSCIENCE ANNOUNCES COLLABORATION AGREEMENT WITH CJ CHEILJEDANG, A KOREAN PHARMACEUTICAL GIANT TO USE FIBRIN MICROBEADS (FMB) FOR NOVEL UMBILICAL CORD BLOOD STEM CELL RECOVERY
Read More

 

1-9-08
ORTEC SHAREHOLDERS APPROVE CORPORATE NAME CHANGE TO FORTICELL BIOSCIENCE, INC.
Read More

 

12-5-07
ORTEC SELECTED TO PRESENT AMONG LEADING LIFE SCIENCE COMPANIES AT NEW YORK SOCIETY OF SECURITY ANALYSTS CONFERENCE
Read More

 

10-23-07
ORTEC FILES PMA FOR ORCEL® FOR VLU INDICATION
Read More

 

7-11-07
DR. COSTA PAPASTEPHANOU APPOINTED CEO - Three New Board Members Added -
Read More


6-20-07
Ortec Announces $8.7 Million Private Placement in Conjunction with Agreement to Exchange $43 Million Liability for $10 Million of Convertible Preferred Stock
Read More



2-26-07
Ortec Initiates Pre Market Approval (PMA) Application Filing Seeking Approval for OrCel® in Treating Venous Leg Ulcers
Read More



11-29-06
Ortec and Paul Capital Healthcare to Restructure Existing Financing Agreement
Read More



9-29-06
FDA Issues Approvable Letter to Ortec for Use of Cryopreserved OrCel in EB Patients' Hand Reconstructions and Donor Sites
Read More



9-20-06
Ortec Obtains Second Patent Allowance on Haptide Cell Attchment Technology
Read More



9-12-06
Ortec Announces Positive Results in Confirmatory Venous Leg Ulcer Trial
Read More



8-3-06
Ortec’s FDA Approved Cell Line Plays Pivotal Role in Creation of First Embryonic Stem Cell Lines Fit for Human Clinical Trials
Read More



7-24-06
Ortec Announces Reverse Stock Split



7-6-06
Ortec Issues Update on Its Three Technology Platforms for Regenerative Medicine and Stem Cells



6-22-06
Ortec Initiates Pre-Clinical Animal Study to Evaluate Fibrin Microbead Technology for Stem Cell Regeneration of Non-Union Bone Defects



6-20-06
Ortec to be Granted European Patent on its Fibrin Microbead Enabling Technology for Stem Cell ™ Isolation and Therapy
Read More



6-1-06
Ortec Obtains First U.S. Patent allowance on Haptide™ Cell Attachment Technology
Read More



5-30-06
Ortec Expects to File HDE Application with FDA Requesting Marketing Approval of Cryo OrCel® for Use in EB Patients



5-23-06
Ortec CEO Details Corporate Vision and Mission in Letter to Shareholders.



5-16-06
Animal Studies Show Ortec's Fibrin Microbeads Recover up to Four Times the Number of Stem Cells as Conventional Methods



5-10-06
Results Showing the Ability of Ortec's Fibrin Microbeads Technology to Isolate Adult Stem cells from Blood Published in Bone Marrow Transplantation Journal



4-25-06
Ortec Completes Patient Enrollment for Confirmatory Trial Evaluating OrCel in Healing Venous Ulcers

 

   Home   |   About Us   |   Product & Technology   |   Investor Relations   |   Contact   |   Site Map